Company Encyclopedia
View More
name
United-Guardian
UG.US
United-Guardian, Inc. develops, manufactures, sells, and markets specialty cosmetic ingredients, pharmaceutical products, medical lubricants, and sexual wellness ingredients in the United States and internationally. The company offers cosmetic ingredients, including LUBRAJEL, a line of multifunctional hydrogel formulations for personal care and medical products; B-122, a powdered lubricant used in the manufacture of certain cosmetics, such as pressed powders, eyeliners, and rouges, as well as some industrial products; ORCHID COMPLEX, an oil-based extract of orchids; and LUBRASIL II SB, a special formulation of Lubrajel in which silicone oil is incorporated into a Lubrajel base. It also provides medical lubricant products for catheter lubrication, medical devices, condom lubrication, and oral care under the Lubrajel brand, including Lubrajel MG, Lubrajel MGL, Lubrajel RRCG, Lubrajel RR, Lubrajel RC, Lubrajel RA, Lubrajel Fluid, Lubrajel LC, Lubrajel BA, and Lubrajel FACO.
516.59 B
UG.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
Personal Care ProductsIndustry
Industry Ranking32/53
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE17.85%A
    • Profit Margin19.48%A
    • Gross Margin42.09%B
  • Growth ScoreE
    • Revenue YoY-18.29%E
    • Net Profit YoY-43.76%D
    • Total Assets YoY-8.10%E
    • Net Assets YoY-7.00%D
  • Cash ScoreD
    • Cash Flow Margin513.31%C
    • OCF YoY-18.29%E
  • Operating ScoreB
    • Turnover0.79B
  • Debt ScoreA
    • Gearing Ratio13.12%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    United-Guardian Reports Decline in Q3 2025 Earnings

    United-Guardian (UG) reported a decline in Q3 2025 earnings, with net sales falling to $2.26 million from $3.06 million year-over-year. Net income also decreased to $268,441 from $865,484. The drop in income from operations was attributed to lower sales in cosmetic ingredients and higher operating expenses. Despite these challenges, the company maintains a stable financial position with total assets of $12.18 million and retained earnings of $10.12 million. United-Guardian plans to expand its product lines and address global market challenges, anticipating the launch of its new Natrajel line in 2026.

    Tip Ranks·
    US
    UG
    +2.59%
    Tip Ranks·
    US
    UG
    +2.59%

    United-Guardian | 10-Q: FY2025 Q3 Revenue: USD 2.264 M

    LB filings·
    US
    UG
    +2.59%
    LB filings·
    US
    UG
    +2.59%

    United-Guardian | 8-K: FY2025 Q3 Revenue: USD 2.264 M

    LB filings·
    US
    UG
    +2.59%
    LB filings·
    US
    UG
    +2.59%

    United-Guardian Inc. reports third quarter sales and net income decline

    United-Guardian Inc. reported a decline in third quarter sales and net income for 2025. Net sales fell to $2.3 million from $3.1 million in 2024, while net income decreased to $268,400 ($0.06 per share) from $865,500 ($0.19 per share). For the first nine months, net sales were $7.6 million, down from $9.7 million, and net income dropped to $1.5 million ($0.32 per share) from $2.7 million ($0.60 per share). The company is working to expand its pharmaceutical products and has new marketing agreements for personal care items.

    Reuters·
    US
    UG
    +2.59%
    Reuters·
    US
    UG
    +2.59%

    United-Guardian Inc. Q2 2025: Sales Drop 16% to $2.84M, Net Income Falls 34% to $626.8K, EPS Down to $0.14

    United-Guardian Inc. reported a 16% drop in Q2 2025 sales to $2.84 million and a 34% decline in net income to $626.8K, with EPS falling to $0.14. Year-to-date sales decreased from $6.65 million in 2024 to $5.32 million in 2025. The decline is attributed to reduced demand for cosmetic products in Asia amid global trade uncertainties. However, sales of medical lubricants and pharmaceuticals increased. The company is adapting its strategies to mitigate tariff impacts and expects profitability to continue into 2026.

    Reuters·
    US
    UG
    +2.59%
    Reuters·
    US
    UG
    +2.59%
    © 2025 Longbridge｜Disclaimer